Evaluation of Th1 and Th2 mediated cellular and humoral immunity in patients with COVID-19 following the use of melatonin as an adjunctive treatment

5/17 Late treatment study

Hosseini et al., European Journal of Pharmacology, doi:10.1016/j.ejphar.2021.174193 (Peer Reviewed)
Evaluation of Th1 and Th2 mediated cellular and humoral immunity in patients with COVID-19 following the use of melatonin as an adjunctive treatment

Source PDF Share Tweet

40 hospitalized patients in Iran, 20 treated with melatonin, showing that melatonin attenuated inflammatory cytokines.

Hosseini et al., 5/17/2021, peer-reviewed, 9 authors.

All 9 studies All Outcomes

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Submit